International Immunology, Vol. 15, No. 10, pp. 1183-1194,
October 2003
© 2003 Japanese Society for Immunology
Immunogenicity of Peptide-25 of Ag85B in Th1 development: role of IFN-
1 Division of Immunology, Department of Microbiology and Immunology, and 2 Laboratory of Cell Biology, Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan 3 Institute of Microbial Diseases, Osaka University, Osaka 565-0871, Japan
Correspondence to: K. Takatsu; E-mail, takatsuk{at}ims.u-tokyo.ac.jp
Transmitting editor: S. Koyasu
Ag85B (also known as
antigen or MPT59) is immunogenic, and induces expansion and differentiation of TCRVß11+CD4+ T cells to IFN-
-producing cells in C57BL/6 (I-Ab) mice. We reported that Peptide-25 (amino acids 240254) of Ag85B is a major T cell epitope, and its amino acid residues at position 244, 247, 249 and 252 are I-Ab contact residues. Here we examined roles of IFN-
in the generation of Peptide-25-reactive CD4+ TCRVß11+ T cells and the efficacy of mutant peptides of Peptide-25 for Th1 development in mice other than C57BL/6 mice. Immunization of C57BL/6 mice with Peptide-25 included in incomplete Freunds adjuvant led to preferential induction of CD4+ TCRVß11+ IFN-
- and tumor necrosis factor-
-producing T cells. Compared with other I-Ab-binding peptides such as Peptide-9 of Ag85B, 50V of pigeon cytochrome c and ovalbumin (OVA)265280 peptide, only Peptide-25 was capable of inducing enormous expansion of TCRVß11+ IFN-
-producing T cells. Treatment of C57BL/6 mice with anti-Vß11 antibody before Peptide-25 immunization reduced the development of CD4+ IFN-
-producing T cells. Furthermore, B10.A(3R) mice, I-Ab-positive and TCRVß11 strain, showed remarkably lower response to Peptide-25 immunization than C57BL/6 mice. Peptide-25-primed IFN-
/ cells showed significantly decreased expansion of CD4+ TCRVß11+ T cells as compared with wild-type cells. Interestingly, Peptide-25-primed cells from MyD88-deficient mice responded to Peptide-25 and differentiated into IFN-
-producing cells to a similar extent as wild-type mice, indicating Toll-like receptor-independent IFN-
production. These results imply that IFN-
plays important roles for the generation and expansion of CD4+ TCRVß11+ T cells in response to Peptide-25. Although Peptide-25 was non-immunogenic in C3H/HeN mice, a substituted mutant of Peptide-25, 244D247V, capable of binding to I-Ak, induced Th1 development. These results clearly demonstrate important roles of IFN-
in the expansion of CD4+ TCRVß11+ T cells, and will provide useful information for delineating the regulatory mechanisms of Th1-cell development and for analyzing mechanisms on Th1-dominant immune responses.
Keywords: Ag85B, mycobacterium, subunit vaccine, TCRVß11, tuberculosis
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. S. Andersen, J. Dietrich, E. M. Agger, N. Y. Lycke, K. Lovgren, and P. Andersen The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis Infect. Immun., January 1, 2007; 75(1): 408 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nambu, S. Nakae, and Y. Iwakura IL-1{beta}, but not IL-1{alpha}, is required for antigen-specific T cell activation and the induction of local inflammation in the delayed-type hypersensitivity responses Int. Immunol., May 1, 2006; 18(5): 701 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Takamura, K. Matsuo, Y. Takebe, and Y. Yasutomi Ag85B of Mycobacteria Elicits Effective CTL Responses through Activation of Robust Th1 Immunity as a Novel Adjuvant in DNA Vaccine J. Immunol., August 15, 2005; 175(4): 2541 - 2547. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tamura, H. Ariga, T. Kinashi, S. Uehara, T. Kikuchi, M. Nakada, T. Tokunaga, W. Xu, A. Kariyone, T. Saito, et al. The role of antigenic peptide in CD4+ T helper phenotype development in a T cell receptor transgenic model Int. Immunol., December 1, 2004; 16(12): 1691 - 1699. [Abstract] [Full Text] [PDF] |
||||


